OBJECTIVES: The aim of this study was to iteratively develop and validate an (18)F-labeled small vascular cell adhesion molecule (VCAM)-1 affinity ligand and demonstrate the feasibility of imaging VCAM-1 expression by positron emission tomography-computed tomography (PET-CT) in murine atherosclerotic arteries. BACKGROUND: Hybrid PET-CT imaging allows simultaneous assessment of atherosclerotic lesion morphology (CT) and may facilitate early risk assessment in individual patients. The early induction, confinement of expression to atherosclerotic lesions, and accessible position in proximity to the blood pool render the adhesion molecule VCAM-1 an attractive imaging biomarker for inflamed atheroma prone to complication. METHODS: A cyclic, a linear, and an oligomer affinity peptide, internalized into endothelial cells by VCAM-1-mediated binding, were initially derivatized with DOTA to determine their binding profiles and pharmacokinetics. The lead compound was then (18)F-labeled and tested in atherosclerotic apoE(-/-) mice receiving a high-cholesterol diet as well as wild type murine models of myocardial infarction and heart transplant rejection. RESULTS: The tetrameric peptide had the highest affinity and specificity for VCAM-1 (97% inhibition with soluble VCAM-1 in vitro). In vivo PET-CT imaging using (18)F-4V showed 0.31 +/- 0.02 SUV in murine atheroma (ex vivo %IDGT 5.9 +/- 1.5). (18)F-4V uptake colocalized with atherosclerotic plaques on Oil Red O staining and correlated to mRNA levels of VCAM-1 measured by quantitative reverse transcription polymerase chain reaction (R = 0.79, p = 0.03). Atherosclerotic mice receiving an atorvastatin-enriched diet had significantly lower lesional uptake (p < 0.05). Furthermore, (18)F-4V imaging in myocardial ischemia after coronary ligation and in transplanted cardiac allografts undergoing rejection showed high in vivo PET signal in inflamed myocardium and good correlation with ex vivo measurement of VCAM-1 mRNA by quantitative polymerase chain reaction. CONCLUSIONS: (18)F-4V allows noninvasive PET-CT imaging of VCAM-1 in inflammatory atherosclerosis, has the dynamic range to quantify treatment effects, and correlates with inflammatory gene expression.
OBJECTIVES: The aim of this study was to iteratively develop and validate an (18)F-labeled small vascular cell adhesion molecule (VCAM)-1 affinity ligand and demonstrate the feasibility of imaging VCAM-1 expression by positron emission tomography-computed tomography (PET-CT) in murineatherosclerotic arteries. BACKGROUND: Hybrid PET-CT imaging allows simultaneous assessment of atherosclerotic lesion morphology (CT) and may facilitate early risk assessment in individual patients. The early induction, confinement of expression to atherosclerotic lesions, and accessible position in proximity to the blood pool render the adhesion molecule VCAM-1 an attractive imaging biomarker for inflamed atheroma prone to complication. METHODS: A cyclic, a linear, and an oligomer affinity peptide, internalized into endothelial cells by VCAM-1-mediated binding, were initially derivatized with DOTA to determine their binding profiles and pharmacokinetics. The lead compound was then (18)F-labeled and tested in atheroscleroticapoE(-/-) mice receiving a high-cholesterol diet as well as wild type murine models of myocardial infarction and heart transplant rejection. RESULTS: The tetrameric peptide had the highest affinity and specificity for VCAM-1 (97% inhibition with soluble VCAM-1 in vitro). In vivo PET-CT imaging using (18)F-4V showed 0.31 +/- 0.02 SUV in murineatheroma (ex vivo %IDGT 5.9 +/- 1.5). (18)F-4V uptake colocalized with atherosclerotic plaques on Oil Red O staining and correlated to mRNA levels of VCAM-1 measured by quantitative reverse transcription polymerase chain reaction (R = 0.79, p = 0.03). Atheroscleroticmice receiving an atorvastatin-enriched diet had significantly lower lesional uptake (p < 0.05). Furthermore, (18)F-4V imaging in myocardial ischemia after coronary ligation and in transplanted cardiac allografts undergoing rejection showed high in vivo PET signal in inflamed myocardium and good correlation with ex vivo measurement of VCAM-1 mRNA by quantitative polymerase chain reaction. CONCLUSIONS: (18)F-4V allows noninvasive PET-CT imaging of VCAM-1 in inflammatory atherosclerosis, has the dynamic range to quantify treatment effects, and correlates with inflammatory gene expression.
Authors: Kimberly A Kelly; Jennifer R Allport; Andrew Tsourkas; Vivek R Shinde-Patil; Lee Josephson; Ralph Weissleder Journal: Circ Res Date: 2005-01-13 Impact factor: 17.367
Authors: Matthias Nahrendorf; Farouc A Jaffer; Kimberly A Kelly; David E Sosnovik; Elena Aikawa; Peter Libby; Ralph Weissleder Journal: Circulation Date: 2006-09-25 Impact factor: 29.690
Authors: Beat A Kaufmann; John M Sanders; Christopher Davis; Aris Xie; Patrick Aldred; Ian J Sarembock; Jonathan R Lindner Journal: Circulation Date: 2007-06-25 Impact factor: 29.690
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Cathy Anne Pinto; Christopher Tong; Ash Rafique; Richard Hargeaves; Michael Farkouh; Valentin Fuster; Zahi A Fayad Journal: J Nucl Med Date: 2008-05-15 Impact factor: 10.057
Authors: Koichi Shimizu; Peter Libby; Rica Shubiki; Masashi Sakuma; Yunmei Wang; Kenichi Asano; Richard N Mitchell; Daniel I Simon Journal: Circulation Date: 2008-03-31 Impact factor: 29.690
Authors: Matthias Nahrendorf; David Sosnovik; John W Chen; Peter Panizzi; Jose-Luiz Figueiredo; Elena Aikawa; Peter Libby; Filip K Swirski; Ralph Weissleder Journal: Circulation Date: 2008-02-11 Impact factor: 29.690
Authors: Jennifer M Scalici; Stephanie Thomas; Christine Harrer; Timothy A Raines; Joanna Curran; Kristen A Atkins; Mark R Conaway; Linda Duska; Kimberly A Kelly; Jill K Slack-Davis Journal: J Nucl Med Date: 2013-09-12 Impact factor: 10.057
Authors: Md Imam Uddin; Tyler C Kilburn; Rong Yang; Gary W McCollum; David W Wright; John S Penn Journal: Mol Pharm Date: 2018-10-29 Impact factor: 4.939